Aurinia Pharmaceuticals (AUPH) Stock Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

AUPH Stock Information

Symbol

AUPH

Address

4464 Markham StreetVictoria, BC V8Z 7X8Canada

Founded

Trading hours

Website

https://www.auriniapharma.com

Country

🇨🇦 Canada

Phone Number

250 708 4272

Aurinia Pharmaceuticals (AUPH) Price Chart

Aurinia Pharmaceuticals Overview: Key Details and Summary

Stock data	2023	Change
Price	$7.06	N/A
Market Cap	$1.01B	N/A
Shares Outstanding	143.24M	0.93%
Employees	300.00	N/A

Valuation	2023	Change
P/E Ratio	-13.07	N/A
P/S Ratio	5.76	N/A

Earnings	2023	Change
Revenue	$175.51M	N/A
Earnings	-$78.02M	N/A
EPS	-0.54	N/A
Earnings Yield	-0.0765	N/A
Gross Margin	0.9194	N/A
Operating Margin	-0.5224	N/A
Net income margin	-0.4445	N/A